IBJNews

Lilly continues string of positive trials

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results with results from experimental cancer and diabetes drugs.

The Indianapolis-based drugmaker said Monday its experimental diabetes drug dulaglutide lowered blood sugar in Type 2 diabetics better than three existing diabetes drugs in three Phase 3 clinical trials.

And on Oct. 15, Lilly announced that its cancer drug ramucirumab helped extend survival times for stomach cancer patients in a Phase 3 trial.

The results, when combined with the positive signs Lilly reported from its Alzheimer’s drug solanezumab, present an encouraging pattern that the company’s pipeline-driven strategy may, in fact, have a shot at succeeding. Its a stark reversal from a series of clinical trial failures that Lilly suffered this summer.

“This is great news for the pipeline, which continues the recent news on sola, ramucirumab and bariticinib,” UBS pharmaceutical analyst Marc Goodman said in a note to investors Monday. Baricitinib is another Lilly drug aimed at rheumatoid arthritis.

Investors have had similar thoughts, bidding up Lilly shares 24 percent over the past two months.

But Lilly still has a bit of proving to do. Its Alzheimer’s drug most likely will need to go through another Phase 3 clinical trial before it can win approval from regulators.

Meanwhile, the diabetes drug dulaglutide has to show that it is superior to Bydureon, a similar once-weekly injectable medicine already on the market. Both dulaglutide and Bydureon are known as glucagon-like peptides, or GLP-1 drugs. In 2005, Lilly helped launch the first GLP medicine, Byetta, in partnership with California-based Amylin Pharmaceuticals Inc. The two companies also launched Bydureon, which is a once-weekly version of Byetta, last year.

Patients receiving once-weekly injections of dulaglutide saw their levels of hemoglobin A1C—a key measure of blood sugar—go down more than did patients in the trials taking metformin, Byetta or Januvia.

But how much the levels went down, Lilly isn’t saying. Lilly said it would present more data about dulaglutdie during medical conferences in 2013 and 2014. Lilly plans to file for regulatory approval of dulagrlutide next year.

In its clinical trials, Bydureon also produced lower levels of blood sugar than either Byetta or Januvia, which is a popular oral diabetes medicine made by New Jersey-based Merck & Co. Inc.

Lilly gave up rights to both Byetta and Bydureon last year after a dispute with its former partner on the drugs, California-based Amylin Pharmaceuticals Inc. Lilly received a $250 million break-up fee, and royalties up to $1.2 billion over the life of Byetta.

"We're very encouraged by the results to date from our Phase III dulaglutide trials and are pleased to be one step closer to offering a new GLP-1 treatment option for Type 2 diabetes," Enrique Conterno, president of Lilly’s diabetes division, said in a prepared statement.

And as for the cancer drug ramucirumab, Lilly’s clinical trial data only showed that its drug was better than “best supportive care,” not better than another cancer drug. Lilly is still running a clinical trial that compares ramucirumab against an old cancer drug, paclitaxel.

Results from that second Phase 3 trial are expected a year from now.

“Ramu news encouraging but we need to see more data,” is how Morgan Stanley analyst David Risinger headlined his research note on the drug’s clinical trial results.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. If what you stated is true, then this article is entirely inaccurate. "State sells bonds" is same as "State borrows money". Supposedly the company will "pay for them". But since we are paying the company, we are still paying for this road with borrowed money, even though the state has $2 billion in the bank.

  2. Andrew hit the nail on the head. AMTRAK provides terrible service and that is why the state has found a contractor to improve the service. More trips, on-time performance, better times, cleanliness and adequate or better restrooms. WI-FI and food service will also be provided. Transit from outlying areas will also be provided. I wouldn't take it the way it is but with the above services and marketing of the service,ridership will improve and more folks will explore Indy and may even want to move here.

  3. They could take the property using eminent domain and save money by not paying the church or building a soccer field and a new driveway. Ctrwd has monthly meetings open to all customers of the district. The meetings are listed and if the customers really cared that much they would show. Ctrwd works hard in every way they can to make sure the customer is put first. Overflows damage the surrounding environment and cost a lot of money every year. There have been many upgrades done through the years to help not send flow to Carmel. Even with the upgrades ctrwd cannot always keep up. I understand how a storage tank could be an eye sore, but has anyone thought to look at other lift stations or storage tanks. Most lift stations are right in the middle of neighborhoods. Some close to schools and soccer fields, and some right in back yards, or at least next to a back yard. We all have to work together to come up with a proper solution. The proposed solution by ctrwd is the best one offered so far.

  4. Fox has comments from several people that seem to have some inside information. I would refer to their website. Changed my whole opionion of this story.

  5. This place is great! I'm piggy backing and saying the Cobb salad is great. But the ribs are awesome. $6.49 for ribs and 2 sides?! They're delicious. If you work downtown, head over there.

ADVERTISEMENT